Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials

Απλή σελίδα τεκμηρίου
dc.contributor.authorKosmidis, P. A.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorApostolopoulou, F.en
dc.contributor.authorSkarlos, D.en
dc.date.accessioned2015-11-24T19:30:29Z
dc.date.available2015-11-24T19:30:29Z
dc.identifier.issn0093-7754-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23106
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/administration & dosage/adverse effectsen
dc.subjectCarcinoma, Small Cell/*drug therapy/radiotherapyen
dc.subjectChemotherapy, Adjuvanten
dc.subjectCisplatin/administration & dosage/adverse effectsen
dc.subjectDrug Administration Scheduleen
dc.subjectEtoposide/administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/*drug therapy/radiotherapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectRemission Inductionen
dc.subjectSurvival Analysisen
dc.titleCisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trialsen
heal.abstractThe efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally effective. However, the carboplatin/etoposide regimen caused significantly less nausea, vomiting, nephrotoxicity, and neurotoxicity, and it was easier to administer. Dose intensity and treatment delays were similar in both groups. Thoracic irradiation given concurrently with chemotherapy is feasible and seems to offer a survival advantage. The relapse rate also is lower among patients who have received radiation therapy, and recurrences tended to be outside of the lung. Overall, a survival benefit was identified for patients aged between 50 and 65 years who had limited disease, good performance status, and only one metastatic site. Prophylactic brain irradiation in a subset of patients reduced brain metastasis, but the difference did not reach significance. From this trial, it is concluded that carboplatin/etoposide combination therapy is highly effective and is well tolerated by patients with small cell lung cancer. In limited disease, this combination can be given concurrently with thoracic irradiation and offers a survival advantage.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8052870-
heal.journalNameSemin Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1994-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ